Apexigen today announced a collaboration with Columbia University Irving Medical Center on a new Phase 2 study for its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40, in combination with doxorubicin and olaratumab in patients with advanced sarcomas. The trial is being funded by Apexigen and is being conducted by researchers at Columbia[…]
Apexigen today announced the successful completion of its Series B and Series C financings in which it raised a total of $73 million. The $15 million Series B financing was led by Decheng Capital and the recent $58 million Series C financing was led by 3E Bioventures Capital, Virtus Inspire Ventures, and SV Tech Ventures.[…]
San Carlos, CA, and New Haven, CT – June 14, 2018 Apexigen and Yale Cancer Center today announced a clinical trial collaboration to evaluate Apexigen’s APX005M in combination with cabiralizumab and Opdivo in patients with advanced solid tumors. The Phase 1/2 clinical trial will evaluate the safety, tolerability, and preliminary activity of APX005M in combination with cabiralizumab[…]
Apexigen today announced the initiation of patient enrollment in Phase 2 clinical trial in collaboration with the University of California San Francisco (UCSF). This trial is designed to evaluate Apexigen’s CD40 agonistic antibody, APX005M, in combination with multimodal treatment (chemotherapy and radiation therapy) in patients with resectable esophageal and gastroesophageal junction cancers.
Apexigen, Inc., — a clinical-stage biopharmaceutical company focusing on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology (I-O) agents, today announced the receipt of a milestone payment under a license agreement for its proprietary APXiMAB™ technology. The milestone payment was associated with the achievement of a clinical development[…]